These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 18753646)

  • 1. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy.
    Rouse DJ; Hirtz DG; Thom E; Varner MW; Spong CY; Mercer BM; Iams JD; Wapner RJ; Sorokin Y; Alexander JM; Harper M; Thorp JM; Ramin SM; Malone FD; Carpenter M; Miodovnik M; Moawad A; O'Sullivan MJ; Peaceman AM; Hankins GD; Langer O; Caritis SN; Roberts JM;
    N Engl J Med; 2008 Aug; 359(9):895-905. PubMed ID: 18753646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial.
    Crowther CA; Hiller JE; Doyle LW; Haslam RR;
    JAMA; 2003 Nov; 290(20):2669-76. PubMed ID: 14645308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes.
    Horton AL; Lai Y; Rouse DJ; Spong CY; Leveno KJ; Varner MW; Mercer BM; Iams JD; Wapner RJ; Sorokin Y; Thorp JM; Ramin SM; Malone FD; O'Sullivan MJ; Hankins GD; Caritis SN;
    Am J Perinatol; 2015 Mar; 32(4):387-92. PubMed ID: 25241107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis.
    Costantine MM; Weiner SJ;
    Obstet Gynecol; 2009 Aug; 114(2 Pt 1):354-364. PubMed ID: 19622997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prenatal Intravenous Magnesium at 30-34 Weeks' Gestation and Neurodevelopmental Outcomes in Offspring: The MAGENTA Randomized Clinical Trial.
    Crowther CA; Ashwood P; Middleton PF; McPhee A; Tran T; Harding JE;
    JAMA; 2023 Aug; 330(7):603-614. PubMed ID: 37581672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnesium sulphate at 30 to 34 weeks' gestational age: neuroprotection trial (MAGENTA)--study protocol.
    Crowther CA; Middleton PF; Wilkinson D; Ashwood P; Haslam R;
    BMC Pregnancy Childbirth; 2013 Apr; 13():91. PubMed ID: 23570677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnesium sulfate for the prevention of cerebral palsy.
    Mittendorf R; Pryde PG
    N Engl J Med; 2009 Jan; 360(2):189-90; author reply 190. PubMed ID: 19129535
    [No Abstract]   [Full Text] [Related]  

  • 8. Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants.
    Mittendorf R; Dambrosia J; Pryde PG; Lee KS; Gianopoulos JG; Besinger RE; Tomich PG
    Am J Obstet Gynecol; 2002 Jun; 186(6):1111-8. PubMed ID: 12066082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maternal obesity and neuroprotective magnesium sulfate.
    McPherson J; Smiley S; Stamilio D
    Am J Obstet Gynecol; 2015 Oct; 213(4):582.e1-6. PubMed ID: 26116874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In defense of magnesium sulfate.
    Elliott JP; Lewis DF; Morrison JC; Garite TJ
    Obstet Gynecol; 2009 Jun; 113(6):1341-1348. PubMed ID: 19461432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Committee Opinion No. 455: Magnesium sulfate before anticipated preterm birth for neuroprotection.
    Obstet Gynecol; 2010 Mar; 115(3):669-671. PubMed ID: 20177305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antenatal magnesium sulfate for neuroprotection before preterm birth?
    Stanley FJ; Crowther C
    N Engl J Med; 2008 Aug; 359(9):962-4. PubMed ID: 18753653
    [No Abstract]   [Full Text] [Related]  

  • 13. Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes.
    McPherson JA; Rouse DJ; Grobman WA; Palatnik A; Stamilio DM
    Obstet Gynecol; 2014 Oct; 124(4):749-755. PubMed ID: 25198275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo.
    Doyle LW; Anderson PJ; Haslam R; Lee KJ; Crowther C;
    JAMA; 2014 Sep; 312(11):1105-13. PubMed ID: 25226476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnesium sulphate for preventing preterm birth in threatened preterm labour.
    Crowther CA; Brown J; McKinlay CJ; Middleton P
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD001060. PubMed ID: 25126773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants.
    Mittendorf R; Pryde PG; Lee KS
    Am J Obstet Gynecol; 2003 Aug; 189(2):613. PubMed ID: 14524362
    [No Abstract]   [Full Text] [Related]  

  • 17. Magnesium sulfate, chorioamnionitis, and neurodevelopment after preterm birth.
    Kamyar M; Manuck TA; Stoddard GJ; Varner MW; Clark E
    BJOG; 2016 Jun; 123(7):1161-6. PubMed ID: 26036660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnesium sulfate for cerebral palsy prevention.
    Rouse DJ; Gibbins KJ
    Semin Perinatol; 2013 Dec; 37(6):414-6. PubMed ID: 24290398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low-birth-weight children aged 3 to 5 years.
    Schendel DE; Berg CJ; Yeargin-Allsopp M; Boyle CA; Decoufle P
    JAMA; 1996 Dec; 276(22):1805-10. PubMed ID: 8946900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fetal pharmacotherapy 3: magnesium sulfate.
    Namouz-Haddad S; Koren G
    J Obstet Gynaecol Can; 2013 Dec; 35(12):1101-1104. PubMed ID: 24405877
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.